A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

被引：1
|
作者：
Ross, David M. [1 ]
Arbelaez, Alejandro [2 ]
Chee, Lynette C. Y. [3 ]
Fong, Chun Yew [4 ]
Hiwase, Devendra [5 ]
Kannourakis, George [6 ]
Kwan, John [7 ]
Liang, James [8 ]
Puliyayi, Anish [9 ]
Rose, Hannah [10 ]
Tan, Shuhying [11 ]
Teh, Tse-Chieh [12 ]
esterman, David Alan [13 ]
Wight, Joel
Rovaldi, Chris
Furutani, Elissa M.
Gaggi, Adrienne
Jiang, Ying
Lachey, Jenn
Natarajan, Harveen Dhillon
Ordonez, Claudia
机构：
[1] Flinders Med Ctr & Univ, Dept Haematol, Adelaide, SA, Australia
[2] Tweed Hosp, Brisbane, Qld, Australia
[3] Peter MacCallum Canc Ctr & Royal Melbourne Hosp, Dept Clin Haematol & Bone Marrow Transplant Serv, Melbourne, Vic, Australia
[4] Austin Hlth & Olivia Newton John Canc Res Inst, Dept Clin Haematol, Melbourne, Australia
[5] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia
[6] Ballarat Onc & Hem Serv, Ballarat, Vic, Australia
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Middlemore Hosp, Auckland, New Zealand
[9] Barwon Hlth, Geelong, Vic, Australia
[10] Box Hill Hosp, Victoria, Australia
[11] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
[12] Townsville Univ Hosp, NS Biopharma Marblehead MA, Townsville, Qld, Australia
[13] Keros Therapeut, Lexington, MA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147335
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3675
引用
收藏
页码：3675 / +
页数：5
相关论文
共 50 条
  • [31] Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
    Can, Adem T.
    Hermens, Daniel F.
    Dutton, Megan
    Gallay, Cyrana C.
    Jensen, Emma
    Jones, Monique
    Scherman, Jennifer
    Beaudequin, Denise A.
    Yang, Cian
    Schwenn, Paul E.
    Lagopoulos, Jim
    TRANSLATIONAL PSYCHIATRY, 2021, 11 (01)
  • [32] Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study
    Thomas Paparrigopoulos
    Elias Tzavellas
    Dimitris Karaiskos
    Georgia Kourlaba
    Ioannis Liappas
    BMC Psychiatry, 11
  • [33] Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata
    Eisinger, Steve H.
    Fiscella, Julietta
    Bonfiglio, Thomas
    Meldrum, Sean
    Fiscella, Kevin
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, 146 (02) : 215 - 218
  • [34] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    BLOOD, 2014, 124 (21)
  • [35] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Fenaux, Pierre
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    Finelli, Carlo
    Giagounidis, Aristoteles
    Schoch, Robert
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Bennett, John M.
    Byrd, John
    Backstrom, Jay
    Zimmerman, Linda
    McKenzie, David
    Beach, C. L.
    Silverman, Lewis R.
    LANCET ONCOLOGY, 2009, 10 (03) : 223 - 232
  • [36] Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload
    Du, Yali
    Long, Zhangbiao
    Chen, Miao
    Han, Bing
    Hou, Bo
    Feng, Feng
    ACTA HAEMATOLOGICA, 2017, 138 (02) : 119 - 128
  • [37] Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
    Stasi, R
    Abruzzese, E
    Lanzetta, G
    Terzoli, E
    Amadori, S
    ANNALS OF ONCOLOGY, 2005, 16 (12) : 1921 - 1927
  • [38] Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
    Al-Kali, Aref
    Saliba, Antoine
    Yi, Cecilia Y. Arana
    Foran, James M.
    Tanoue, Yasushi
    Yamamoto, Maki
    Gullbo, Joachim
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [39] Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
    Natarajan-Ame, Shanti
    Park, Sophie
    Ades, Lionel
    Vey, Norbert
    Guerci-Bresler, Agnes
    Cahn, Jean-Yves
    Etienne, Gabriel
    Bordessoule, Dominique
    Ravoet, Christophe
    Legros, Laurence
    Cheze, Stephane
    Stamatoullas, Aspasia
    Berger, Elisabeth
    Schmidt, Aline
    Charbonnier, Aude
    Chaury, Marie-Pierre
    Braun, Thorsten
    Fenaux, Pierre
    Dreyfus, Francois
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 232 - 237
  • [40] An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
    Savona, Michael R.
    Odenike, Olatoyosi
    Amrein, Philip C.
    Steensma, David P.
    DeZern, Amy E.
    Michaelis, Laura C.
    Faderl, Stefan
    Harb, Wael
    Kantarjian, Hagop
    Lowder, James
    Oganesian, Aram
    Azab, Mohammad
    Garcia-Manero, Guillermo
    LANCET HAEMATOLOGY, 2019, 6 (04): : E194 - E203
12345